{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non-Hodgkin+Lymphoma+%28B-NHL%29&page=14", "query": { "condition": "B-cell Non-Hodgkin Lymphoma (B-NHL)", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 1092, "total_pages": 110, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non-Hodgkin+Lymphoma+%28B-NHL%29&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non-Hodgkin+Lymphoma+%28B-NHL%29&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T05:49:01.597Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004189", "title": "Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "becatecarin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-10-14T05:49:01.597Z", "location_count": 3, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004189" }, { "nct_id": "NCT03749018", "title": "Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aggressive Non-Hodgkin Lymphoma", "Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Indolent Non-Hodgkin Lymphoma", "Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma", "Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "David Bond, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-01-02", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-14T05:49:01.597Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03749018" }, { "nct_id": "NCT03017820", "title": "A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Non-Hodgkin Lymphoma", "Histiocytic and Dendritic Cell Neoplasm", "Myelodysplastic Syndrome", "Previously Treated Myelodysplastic Syndrome", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Anaplastic Large Cell Lymphoma", "Recurrent Angioimmunoblastic T-Cell Lymphoma", "Recurrent Mycosis Fungoides", "Recurrent Plasma Cell Myeloma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Refractory Acute Myeloid Leukemia", "Refractory Anaplastic Large Cell Lymphoma", "Refractory Angioimmunoblastic T-Cell Lymphoma", "Refractory Mycosis Fungoides", "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Refractory Plasma Cell Myeloma", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory T-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter", "type": "BIOLOGICAL" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2017-04-04", "completion_date": "2032-04-01", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-14T05:49:01.597Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03017820" }, { "nct_id": "NCT00005959", "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-10-14T05:49:01.597Z", "location_count": 27, "location_summary": "Montgomery, Alabama • Little Rock, Arkansas • Burbank, California + 24 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005959" }, { "nct_id": "NCT05169515", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "SC Mosunetuzumab", "type": "DRUG" }, { "name": "IV Glofitamab", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "Golcadomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2022-10-26", "completion_date": "2029-08-05", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-14T05:49:01.597Z", "location_count": 6, "location_summary": "San Francisco, California • Aurora, Colorado • Tampa, Florida + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169515" }, { "nct_id": "NCT03844048", "title": "An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Acute Myeloid Leukemia", "Multiple Myeloma", "Non-Hodgkin's Lymphoma", "Acute Lymphoblastic Leukemia", "Cancer" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 165, "start_date": "2019-09-06", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-14T05:49:01.597Z", "location_count": 7, "location_summary": "Tucson, Arizona • Los Angeles, California • Harvey, Illinois + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03844048" }, { "nct_id": "NCT00008216", "title": "Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adult Langerhans Cell Histiocytosis", "Childhood Langerhans Cell Histiocytosis", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "1996-07", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2014-06-06", "last_synced_at": "2026-10-14T05:49:01.597Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00008216" }, { "nct_id": "NCT02952508", "title": "Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenstrom Macroglobulinemia", "Multiple Myeloma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Lymphoplasmacytic Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Diffuse Large B Cell Lymphoma", "Central Nervous System Lymphoma" ], "interventions": [ { "name": "Iopofosine I 131 single dose", "type": "DRUG" }, { "name": "Iopofosine I 131 multiple dose", "type": "DRUG" }, { "name": "Iopofosine I 131 fractionated dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellectar Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2017-07-26", "completion_date": "2027-12-22", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-14T05:49:01.597Z", "location_count": 29, "location_summary": "Los Angeles, California • Redlands, California • Washington D.C., District of Columbia + 25 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02952508" }, { "nct_id": "NCT04504708", "title": "Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "ZX-101A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hangzhou Zenshine Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-02-17", "completion_date": "2022-07-08", "has_results": false, "last_update_posted_date": "2022-10-21", "last_synced_at": "2026-10-14T05:49:01.597Z", "location_count": 6, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Long Beach, California + 3 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Brick", "state": "New Jersey" }, { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04504708" }, { "nct_id": "NCT00080847", "title": "S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma" ], "interventions": [ { "name": "oblimersen sodium", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "19 Years to 59 Years" }, "enrollment_count": 160, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-07", "last_synced_at": "2026-10-14T05:49:01.597Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080847" } ] }